Analyst Ratings For Proteostasis Therapeutics (NASDAQ:PTI)
Today, Royal Bank of Canada initiated coverage on Proteostasis Therapeutics (NASDAQ:PTI) with a Outperform with a price target of $11.00.
Some recent analyst ratings include
- 3/9/2018-Royal Bank of Canada initiated coverage with a Outperform rating.
- 12/19/2017-HC Wainwright Reiterated Rating of Buy.
- 4/18/2016-Guggenheim initiated coverage with a Neutral rating.
Recent Insider Trading Activity For Proteostasis Therapeutics (NASDAQ:PTI)
Proteostasis Therapeutics (NASDAQ:PTI) has insider ownership of 17.40% and institutional ownership of 70.48%.
- On 12/18/2017 Enterprise Associates 12 New, Major Shareholder, bought 2,000,000 with an average share price of $5.00 per share and the total transaction amounting to $10,000,000.00.
- On 12/18/2017 Franklin M Berger, Director, bought 60,000 with an average share price of $5.00 per share and the total transaction amounting to $300,000.00.
- On 12/18/2017 Meenu Chhabra, Insider, bought 40,000 with an average share price of $5.00 per share and the total transaction amounting to $200,000.00.
- On 12/14/2017 Cormorant Asset Management, Ll, Major Shareholder, sold 504,027 with an average share price of $4.88 per share and the total transaction amounting to $2,459,651.76.
- On 3/13/2017 Fmr Llc, Insider, sold 25,000 with an average share price of $12.94 per share and the total transaction amounting to $323,500.00.
- On 3/10/2017 Fmr Llc, Insider, sold 25,000 with an average share price of $12.04 per share and the total transaction amounting to $301,000.00.
- On 3/9/2017 Fmr Llc, Insider, sold 29,300 with an average share price of $12.08 per share and the total transaction amounting to $353,944.00.
Recent Trading Activity for Proteostasis Therapeutics (NASDAQ:PTI)
Shares of Proteostasis Therapeutics closed the previous trading session at 3.92 up +0.31 8.59% with 3.8499999046325684 shares trading hands.
